Free Trial

Aligos Therapeutics (ALGS) SEC Filings & 10K Form

Aligos Therapeutics logo
$7.46 +0.18 (+2.47%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.47 +0.01 (+0.13%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Aligos Therapeutics SEC Filings

DateFilerForm TypeView
07/18/2025
4:14 PM
Aligos Therapeutics (Issuer)
Symons Julian A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025
4:14 PM
Aligos Therapeutics (Issuer)
BLATT LAWRENCE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025
3:41 PM
Aligos Therapeutics (Issuer)
Calhoun Lesley Ann (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:29 PM
Aligos Therapeutics (Issuer)
Martell Bridget A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:29 PM
Aligos Therapeutics (Issuer)
Chavez Margarita (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:30 PM
Aligos Therapeutics (Issuer)
Preston Heather (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:30 PM
Aligos Therapeutics (Issuer)
Hirth Peter (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:30 PM
Aligos Therapeutics (Issuer)
Scopa James Paul (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:31 PM
Aligos Therapeutics (Issuer)
Nuechterlein Carole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:09 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025
12:53 PM
Aligos Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
Form SCHEDULE 13G/A
05/15/2025
8:33 AM
Aligos Therapeutics (Subject)
Woodline Partners LP (Filed by)
Form SCHEDULE 13G
05/06/2025
7:14 AM
Aligos Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2025
7:00 AM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2025
3:12 PM
Aligos Therapeutics (Filer)
Form ARS
04/28/2025
3:15 PM
Aligos Therapeutics (Filer)
Form DEFA14A
04/03/2025
11:15 PM
Aligos Therapeutics (Filer)
Form EFFECT
04/03/2025
3:23 PM
Aligos Therapeutics (Filer)
Form 424B3
03/12/2025
7:30 PM
Aligos Therapeutics (Subject)
BLATT LAWRENCE (Filed by)
Form SCHEDULE 13D/A
03/10/2025
7:00 AM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2025
7:07 AM
Aligos Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/12/2025
8:32 AM
Adage Capital Management, L.P. (Filed by)
Aligos Therapeutics (Subject)
Form SCHEDULE 13G/A
02/12/2025
7:52 AM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/03/2025
3:02 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2024
11:15 PM
Aligos Therapeutics (Filer)
Form EFFECT
11/14/2024
5:57 PM
Aligos Therapeutics (Subject)
Vivo Capital Fund VIII, L.P. (Filed by)
Form SC 13G/A
11/14/2024
5:19 PM
Aligos Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G/A
11/14/2024
3:34 PM
Aligos Therapeutics (Subject)
HHLR ADVISORS, LTD. (Filed by)
Form SC 13G/A
11/12/2024
8:31 AM
Adage Capital Management, L.P. (Filed by)
Aligos Therapeutics (Subject)
Form SC 13G
11/06/2024
4:20 PM
Aligos Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/06/2024
4:14 PM
Aligos Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/06/2024
3:24 PM
Aligos Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
3:05 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2024
3:16 PM
Achneck Hardean (Reporting)
Aligos Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/26/2024
3:15 PM
Achneck Hardean (Reporting)
Aligos Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/06/2024
3:22 PM
Aligos Therapeutics (Issuer)
Symons Julian A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/06/2024
3:23 PM
Aligos Therapeutics (Issuer)
BLATT LAWRENCE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/06/2024
3:23 PM
Aligos Therapeutics (Issuer)
Calhoun Lesley Ann (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
3:06 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/19/2024
3:05 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2024
3:14 PM
Aligos Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
This Crypto Is Set to Explode in January (Ad)

This Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.

Click here to claim your free seat!
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ALGS) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners